It was inevitable. When a U.S. circuit court decided protected a pharma sales rep from off-label marketing charges, the free-speech arguments had to multiply. And they have, in cases across the country, testing that Second Circuit decision in other regions.
The latest: jumped into a California False Claims Act (FCA) case, with a friend-of-the-court brief defending , and 's right to talk up unapproved uses of the clot-fighting drug .
It's a wisely chosen target: The case, filed by former sales rep Frank Solis, hinges on journal articles that the company allegedly distributed to doctors, along with letters summarizing the studies. copromoted with Millennium, and ($MRK) bought Schering in 2009.
http://www.fiercepharmamarketing.com/story/phrma-jumps-integrilin-label-case-free-speech-arguments-ready/2014-08-27?utm_medium=nl&utm_source=internal
The latest: jumped into a California False Claims Act (FCA) case, with a friend-of-the-court brief defending , and 's right to talk up unapproved uses of the clot-fighting drug .
It's a wisely chosen target: The case, filed by former sales rep Frank Solis, hinges on journal articles that the company allegedly distributed to doctors, along with letters summarizing the studies. copromoted with Millennium, and ($MRK) bought Schering in 2009.
http://www.fiercepharmamarketing.com/story/phrma-jumps-integrilin-label-case-free-speech-arguments-ready/2014-08-27?utm_medium=nl&utm_source=internal
No comments:
Post a Comment